United Therapeutics Corporation (UTHR)

NMS – Real Time Price. Currency in USD

542.66

-0.73 (-0.13%)

At close: Jun 26, 2026, 4:00 PM EDT

542.66

0.00 (0.00%)

After-hours: Jun 26, 2026, 6:27 PM EDT

09.06.2026

These 3 Stocks Lowered Their Share Counts Drastically in Q1

While markets often view large-scale buyback authorizations as positives in and of themselves, authorizations are just one part of the buyback equation. Unlike dividends, which companies must pay after declaring, there is no hard requirement for companies to spend the buyback capacity they authorize.

05.06.2026

Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

04.06.2026

SDZNY or UTHR: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?

03.06.2026

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

29.05.2026

Jim Simons' fund bet early on Micron; Here's the fund's top stocks now

While the latest stock market upsurge turned Micron (NASDAQ: MU) into a household name, Jim Simons made a prodigious investment in the memory company as far back as 2013 – when it was trading at approximately $18 – and saw the equity rise almost exactly 5,000% since.

27.05.2026

United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on Wednesday, June 3, 2026, from 12:45 to 1:15 p.m. EST, at the Jefferies Global Healthcare Conference in New York. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archive.

19.05.2026

United Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Videos

No Data

There is no data to display

Press releases

18.05.2026

United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medicine has published the full results of its TETON-1 study, as well as combined analyses of its TETON-1 and TETON-2 studies, evaluating the use of nebulized Tyvaso for the treatment of IPF. The publication is available here. A summary of the publication was also presented today during a symposium at th.

17.05.2026

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being presented today during the Breaking News: 2026 Clinical Trial Results in Pulmonary Medicine session at the annual meeting of the American Thoracic Society (ATS) International Conference in Orlando. Ralinepag has not been approved for use in any indication by the U.S. Food and Dr.

15.05.2026

United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company's Investigational New Drug application to proceed with a clinical study of its investigational UHeart™ derived from a pig with 10 gene edits. The study, known as EXPRESS, will enroll an initial cohort of up to two participants. United Therapeutics.

11.05.2026

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando. “We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieve.

United Therapeutics Corporation (UTHR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

United Therapeutics Corporation (UTHR)

These 3 Stocks Lowered Their Share Counts Drastically in Q1

Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?

SDZNY or UTHR: Which Is the Better Value Stock Right Now?

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Jim Simons' fund bet early on Micron; Here's the fund's top stocks now

United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference

United Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Videos

No Data

Press releases

United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

These 3 Stocks Lowered Their Share Counts Drastically in Q1

Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?

SDZNY or UTHR: Which Is the Better Value Stock Right Now?

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Jim Simons' fund bet early on Micron; Here's the fund's top stocks now

United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference

United Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Videos

No Data

Press releases

United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

Search stocks

United Therapeutics Corporation (UTHR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

United Therapeutics Corporation (UTHR)

These 3 Stocks Lowered Their Share Counts Drastically in Q1

Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?

SDZNY or UTHR: Which Is the Better Value Stock Right Now?

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Jim Simons' fund bet early on Micron; Here's the fund's top stocks now

United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference

United Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Videos

No Data

Press releases

United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

These 3 Stocks Lowered Their Share Counts Drastically in Q1

Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?

SDZNY or UTHR: Which Is the Better Value Stock Right Now?

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Jim Simons' fund bet early on Micron; Here's the fund's top stocks now

United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference

United Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Videos

No Data

Press releases

United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026